"Glenmark Therapeutics Inc., USA (Glenmark) announced the launch of polyethylene glycol 3350, powder for solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX powder for solution, 17 grams of Bayer HealthCare LLC.
According to Nielsen syndicated data for the latest 52 weeks’ period ending February 22, 2025, the MiraLAX powder for solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million.
Commenting on the launch, Marc Kikuchi, president & business head, North America said, “We are excited to announce the launch of polyethylene glycol 3350, powder for solution, 17 grams/capful, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.”
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!